Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2022-12-16 Regulatory Filings
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date and shareholder register closure for the purpose of holding an upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal regulatory notification of the administrative process. Given it is a standard regulatory announcement that does not fit into specific categories like AGM-R (presentation) or PSI (proxy solicitation), it falls under the general regulatory filing category.
2022-12-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share ownership and changes in holdings (specifically stock option exercises) by an executive (Byung Geon Rhee) of Genome & Company. This type of filing is a standard disclosure for insider trading or changes in director/executive shareholdings, which corresponds to the 'Director's Dealing' category.
2022-12-08 Korean
투자판단관련주요경영사항(마이크로바이옴 면역항암 치료제 GEN-001의 고형암 환자 대상 임상1/1b상 시험 조기 종료)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Genome & Company) regarding a material management decision, specifically the early termination of a clinical trial (GEN-001). This type of disclosure is a standard regulatory announcement regarding business operations and clinical trial status, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A, dividends, or financial reports.
2022-12-06 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal notice announcing an upcoming Investor Relations (IR) presentation/briefing session. It provides the date, time, location (online), and the agenda for the session. Since it is an announcement of an event rather than the presentation slides themselves, and it is a regulatory disclosure of an IR event, it fits the 'Regulatory Filings' (RNS) category as a general announcement of corporate activity.
2022-12-06 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Genome & Company, covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-28 Korean
투자판단관련주요경영사항(마이크로바이옴 면역항암 치료제 GEN-001의 담도암 환자 대상 국내 제2상 임상시험계획 (IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Genome & Company) regarding the approval of a Phase 2 clinical trial (IND) for a drug candidate. It is a formal disclosure of a material business event ('투자판단 관련 주요경영사항'). Since it does not fit into specific categories like financial reports, M&A, or shareholder meetings, and is a standard regulatory disclosure of a business development, it falls under the 'Regulatory Filings' category.
2022-11-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.